Reports link bone-building drugs to rare leg fracture

07/15/2008 | NYTimes.com

Case studies on a rare type of leg fracture after little or no trauma among people who took bisphosphonates for five years or more have raised concerns that long-term use of the bone-building drugs may actually weaken bones. Merck & Co.'s Fosamax was cited in the reports, and the company said it will investigate whether the fracture pattern can be found commonly in people who take bone medicines.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ